Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3 and A have the significance given in the specification are provided. The compounds can be used for the treatment or prevention of obesity.

Abstract: The invention relates to a rheological additive comprising illite clay, smectic clay and an attapulgite suitable for controlling the application characteristics of a coating material for porous bodies.

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Abstract: A method for the production of an extract of Phyllanthus wherein (a) Phyllanthuscomponents are extracted with an ethanol/water mixture of 5–85% m/m to which a heavy-metal chelator is added at a concentration of 0.001–3% m/m; (b) the primary extract obtained in step (a) is contacted and concentrated with (ba) Indian Sterculia gum at a final concentration of 0.5–5.0% mm relative to the sum of the extractive substances or (bb) one or more polymers and impendable and/or soluble substance(s); and (c) the concentrated extract obtained in step (b) is dried. The method according to the invention leads to particularly high yield of pharmaceutically effective plant ingredients and is thus of particular interest for therapeutic applications. In a preferred embodiment of the invention the method according to the invention includes a filtration step of the primary extract. It is further preferred that a lipoid is added during the extraction method. The Phyllanthus Phyllanthus amarus is preferred.

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Abstract: Provided are compounds of the formula I: and pharmaceutically acceptable salts thereof, processes for making said compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compound and pharmaceutically acceptable salts thereof, and methods of using said compounds. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

Abstract: A multiple transaction quantity inventory management system including an inventory management component to store and manage inventory information using a base unit of measure (“UOM”) and in a valuation UOM related by at least one conversion factor for each of a plurality of goods; a material management component connected to the inventory management component, the material management component to monitor and maintain information on the plurality of goods in the base UOM and in the valuation UOM for each of the plurality of goods; a sales delivery component connected to the inventory management component, the sales delivery component to receive and process sales orders in the base UOM; a warehouse management component connected to the inventory management component, the warehouse management component to control stock information for the plurality of goods in a single UOM; and a financial component connected to the inventory management component, the material management component, the sales delivery component,

Abstract: The present invention is a chemical compound of formula (I) or a pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R4, A1, A2 m and n are as described in the specification.

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Abstract: The invention concerns a decorated article, in particular a mobile telephone housing or a mobile telephone window, and a multi-layer film, in particular an IMD-able stamping film. The decorated article has a base body and at least one decorative element arranged on the surface of the base body. The decorative element has a transparent structure layer which has a spatial structure producing an optically perceptible effect, and a reflection layer arranged between the surface of the base body and the structure layer.

Abstract: Quinoline and quinazoline derivatives can be used in the form of pharmaceutical preparations as Neuropeptide Y antagonists for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Abstract: The present invention relates to compounds of formula (I) 1

Abstract: Compounds of formula I 1

Abstract: The present invention is a chemical compound of formula (I) 1

Abstract: A coating material for interior walls and exterior facades has heat reflection and oleophobicity/hydrophobicity, properties. The material is either opaque to visible light and/or contains a material which provides opacity. It includes: a) at least one silane of the formula (I) XaRbSiR14−a−b  (I)  in which X is a hydrolyzable group, R is optionally substituted alkyl, alkenyl, aryl, alkylaryl or arylalkyl, R1 is an organic radical which is attached to the silicon via carbon and carries a reactive group, a is an integer from 1 to 3, and b is an integer from 0 to 2, or a (partial) condensate of this silane, b) at least one infrared-reflecting pigment whose particle size is situated primarily in the range from 1 to 50 &mgr;m, and c) a solvent and/or dispersion medium.

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Abstract: Compounds of formula I 1

Abstract: Compounds of general formula I as well as pharmaceutically acceptable salts and esters thereof, are potent inhibitors of neuropeptide Y and can be used in the form of pharmaceutical preparations for the treatment or prevention of various disease states and related morbidities including obesity.

Abstract: A method for the production of an extract of Phyllanthus wherein (a) Phyllanthus components are extracted with an ethanol/water mixture of 5-85% m/m to which a heavy-metal chelator is added at a concentration of 0.001-3% m/m; (b) the primary extract obtained in step (a) is contacted and concentrated with (ba) Indian Sterculia gum at a final concentration of 0.5-5.0% mm relative to the sum of the extractive substances or (bb) one or more polymers and impendable and/or soluble substance(s); and (c) the concentrated extract obtained in step (b) is dried. The method according to the invention leads to particularly high yield of pharmaceutically effective plant ingredients and is thus of particular interest for therapeutic applications. In a preferred embodiment of the invention the method according to the invention includes a filtration step of the primary extract. It is further preferred that a lipoid is added during the extraction method. The Phyllanthus Phyllanthus amarus is preferred.

Abstract: The present application relates to compounds of the formula wherein R1 is hydrogen, halogen or lower alkoxy; R2 is hydrogen or is —C(O)-lower alkyl or —C(O)-phenyl, wherein the phenyl ring is unsubstituted or substituted by one or two substituents selected from the group consisting of halogen, lower alkyl, lower alkoxy and trifluoromethyl, or is —C(O)-furanyl or —C(O)-thiophenyl, wherein the rings are unsubstituted or substituted by halogen; or a pharmaceutically acceptable salt thereof. The compounds are useful in the treatment of diseases associated with the adenosine A2 receptor.